STC-1 Syngeneic Model Service for Small Intestinal Neuroendocrine Carcinoma

The STC-1 Syngeneic Model Service for Small Intestinal Neuroendocrine Carcinoma supplies a rare, well-characterized enteroendocrine tumor system for preclinical evaluation of therapies targeting neuroendocrine malignancies. Alfa Cytology delivers this model as a complete service offering — immunocompetent C57BL/6 host preparation, tumor implantation and monitoring, treatment administration, and multimodal endpoint analysis — so that neuroendocrine oncology programs gain reliable in vivo evidence with minimal operational burden.

Overview of STC-1 Syngeneic Model for Small Intestinal Neuroendocrine Carcinoma

STC-1 is a murine enteroendocrine tumor cell line established in 1990 by Rindi and colleagues from duodenal neuroendocrine tumors that arose spontaneously in double-transgenic C57BL/6J mice expressing the rat insulin promoter-driven simian virus 40 (SV40) large T antigen together with the murine polyomavirus small T antigen. The resulting cells recapitulate the neuroendocrine adenoma phenotype of the parental intestinal tract tumors: they are adherent and epithelial-like, grow relatively slowly with a doubling time of about 54 hours, and — most distinctively — secrete a repertoire of gut hormones including cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), secretin, somatostatin, and peptide YY, which has made them a reference system for enteroendocrine cell biology in vitro.

Fig 1. In vivo bioluminescence imaging of STC-1 tumors implanted via subcutaneous, renal capsule, and orthotopic pancreatic routes: IVIS signals localized to S/K/P regions at 6 weeks, with one orthotopic case showing metastatic spread (arrow), and ex vivo tumor size confirming most aggressive growth in the orthotopic STC-1 model. (Moccia, Matthew C., et al., 2026)

Because STC-1 derives from the widely used C57BL/6 background, it is uniquely suited among neuroendocrine tumor lines for syngeneic implantation into immunocompetent recipients, enabling study designs that preserve full tumor–immune interactions — a property largely absent from patient-derived xenograft or immunodeficient-host systems. Subcutaneous implantation of STC-1 cells in C57BL/6 mice produces well-differentiated neuroendocrine tumors with characteristic dense-core secretory granules, while surgical implantation into organ sites such as the pancreas generates orthotopic lesions that closely mimic the architecture and microenvironment of human pancreatic neuroendocrine tumors. Firefly luciferase/EGFP-tagged STC-1 derivatives further allow longitudinal, non-invasive monitoring in vivo, supporting applications ranging from anti-secretory and anti-proliferative drug testing to immunotherapy evaluation in this historically underserved tumor class.

Cell Line Information: STC-1

STC-1 is one of the few commercially available mouse neuroendocrine tumor lines and the standard enteroendocrine model derived from a defined genetic background. Its principal attributes are compiled below.

Our Services

Alfa Cytology brings specialized expertise to this uncommon model: authenticated, low-passage STC-1 cultures are maintained under strict quality control, and C57BL/6 recipient colonies are managed to support subcutaneous, orthotopic, and reporter-imaging study formats — providing neuroendocrine cancer programs with a dependable in vivo partner from study design through final data delivery.

Workflow of STC-1 Syngeneic Model Construction

Construction of an STC-1 syngeneic study follows a carefully staged process adapted to the slow-growing nature of enteroendocrine tumors. The sequence below summarizes how the model is built and evaluated:

1. Cell Line Verification: STC-1 cultures are authenticated against reference profiles, screened for mycoplasma and other contaminants, and expanded within a defined passage window to conserve their neuroendocrine phenotype.
2. Host Mouse Preparation: C57BL/6 mice are acclimatized under controlled, pathogen-free housing and randomly allocated to experimental groups ahead of implantation.
3. Tumor Cell Implantation: Approximately 1 × 10⁶ STC-1 cells in a small volume of medium (frequently combined with Matrigel) are implanted subcutaneously, or surgically placed under the renal capsule or into the pancreas for orthotopic modeling.
4. Tumor Establishment Period: Implant sites are monitored for engraftment; because of the line’s slow proliferation, a longer establishment window than for fast-growing carcinomas is planned before measurable tumors appear.
5. Randomization and Dosing: Animals are re-randomized once tumors reach the predetermined size, and treatment with vehicle, reference agents, or test articles begins on the scheduled regimen.
6. In-Life Monitoring: Tumor dimensions, body weight, and clinical status are recorded at defined intervals; luciferase-tagged cohorts undergo serial bioluminescence imaging in vivo to track tumor burden non-invasively.
7. Necropsy and Histopathology: At study end, tumors are excised and weighed; tissues are fixed for hematoxylin and eosin staining, neuroendocrine marker immunohistochemistry (e.g., synaptophysin, chromogranin A), and hormone-level measurements as required.
8. Analysis and Reporting: Tumor-growth kinetics, imaging signals, and endpoint data are statistically analyzed and consolidated into a final study report.

Fig 2. STC-1 Syngeneic Model construction workflow.

Case Study-STC-1 Syngeneic Model Development

In a recent preclinical collaboration, Alfa Cytology implemented the STC-1 syngeneic model for a sponsor developing a therapeutic candidate in the neuroendocrine tumor space. The scope encompassed establishment of tumors in immunocompetent C57BL/6 mice, structured allocation of vehicle and treatment arms, periodic monitoring of tumor development and animal condition, and terminal characterization of harvested tumors with neuroendocrine-marker analysis — producing an integrated results package that supported the client’s preclinical decision-making. Case designs can be configured around growth-inhibition, anti-secretory, combination, or imaging-oriented objectives.

Why Choose Alfa Cytology?

Alfa Cytology pairs uncommon model know-how with disciplined study execution, giving neuroendocrine oncology sponsors confidence in every phase of their in vivo work. Distinct reasons to engage us include:

• Focused experience with STC-1, an enteroendocrine tumor model few providers maintain in active use.
• Genuine immunocompetent modeling in C57BL/6 hosts, enabling immunotherapy-relevant study designs.
• Both subcutaneous and surgical orthotopic implantation capability within one program.
• Reporter-line (luciferase/EGFP) imaging support for longitudinal tumor tracking in vivo.
• Neuroendocrine-aware endpoint panels, including hormone secretion and marker immunohistochemistry.
• Documented quality systems and clear reporting delivered within agreed schedules.

Contact Us

Exploring a preclinical program in small intestinal neuroendocrine carcinoma? The team at Alfa Cytology would be pleased to walk you through the STC-1 syngeneic model and how it can serve your objectives. Contact us for a customized study proposal, or reach out to discuss endpoints, timelines, and budget — we are ready when you are.

For research use only. Not intended for any clinical use.